Ad is loading...
BVNRY
Price
$8.13
Change
-$1.35 (-14.24%)
Updated
Nov 15 closing price
CRMD
Price
$10.33
Change
-$0.67 (-6.09%)
Updated
Nov 15 closing price
134 days until earnings call
Ad is loading...

BVNRY vs CRMD

Header iconBVNRY vs CRMD Comparison
Open Charts BVNRY vs CRMDBanner chart's image
Bavarian Nordic A/S
Price$8.13
Change-$1.35 (-14.24%)
Volume$178.3K
CapitalizationN/A
CorMedix
Price$10.33
Change-$0.67 (-6.09%)
Volume$1.15M
CapitalizationN/A
BVNRY vs CRMD Comparison Chart
Loading...
BVNRY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CRMD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BVNRY vs. CRMD commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BVNRY is a Sell and CRMD is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (BVNRY: $8.13 vs. CRMD: $10.33)
Brand notoriety: BVNRY and CRMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BVNRY: 684% vs. CRMD: 90%
Market capitalization -- BVNRY: $2.28B vs. CRMD: $626.8M
BVNRY [@Biotechnology] is valued at $2.28B. CRMD’s [@Biotechnology] market capitalization is $626.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BVNRY’s FA Score shows that 1 FA rating(s) are green whileCRMD’s FA Score has 0 green FA rating(s).

  • BVNRY’s FA Score: 1 green, 4 red.
  • CRMD’s FA Score: 0 green, 5 red.
According to our system of comparison, BVNRY is a better buy in the long-term than CRMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BVNRY’s TA Score shows that 3 TA indicator(s) are bullish while CRMD’s TA Score has 4 bullish TA indicator(s).

  • BVNRY’s TA Score: 3 bullish, 4 bearish.
  • CRMD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRMD is a better buy in the short-term than BVNRY.

Price Growth

BVNRY (@Biotechnology) experienced а -17.27% price change this week, while CRMD (@Biotechnology) price change was -10.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CRMD is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BVNRY($2.28B) has a higher market cap than CRMD($627M). CRMD YTD gains are higher at: 174.734 vs. BVNRY (-7.033). BVNRY has higher annual earnings (EBITDA): 1.42B vs. CRMD (-47.32M). BVNRY has more cash in the bank: 2.24B vs. CRMD (46M). CRMD has less debt than BVNRY: CRMD (556K) vs BVNRY (125M). BVNRY has higher revenues than CRMD: BVNRY (6.08B) vs CRMD (12.3M).
BVNRYCRMDBVNRY / CRMD
Capitalization2.28B627M363%
EBITDA1.42B-47.32M-2,991%
Gain YTD-7.033174.734-4%
P/E Ratio19.14N/A-
Revenue6.08B12.3M49,455%
Total Cash2.24B46M4,863%
Total Debt125M556K22,482%
FUNDAMENTALS RATINGS
BVNRY vs CRMD: Fundamental Ratings
BVNRY
CRMD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
9670
SMR RATING
1..100
7696
PRICE GROWTH RATING
1..100
6535
P/E GROWTH RATING
1..100
8100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BVNRY's Valuation (57) in the null industry is in the same range as CRMD (71) in the Medical Specialties industry. This means that BVNRY’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's Profit vs Risk Rating (70) in the Medical Specialties industry is in the same range as BVNRY (96) in the null industry. This means that CRMD’s stock grew similarly to BVNRY’s over the last 12 months.

BVNRY's SMR Rating (76) in the null industry is in the same range as CRMD (96) in the Medical Specialties industry. This means that BVNRY’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's Price Growth Rating (35) in the Medical Specialties industry is in the same range as BVNRY (65) in the null industry. This means that CRMD’s stock grew similarly to BVNRY’s over the last 12 months.

BVNRY's P/E Growth Rating (8) in the null industry is significantly better than the same rating for CRMD (100) in the Medical Specialties industry. This means that BVNRY’s stock grew significantly faster than CRMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BVNRYCRMD
RSI
ODDS (%)
Bullish Trend 4 days ago
63%
Bearish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
75%
Momentum
ODDS (%)
Bearish Trend 4 days ago
68%
Bullish Trend 4 days ago
70%
MACD
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
69%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
65%
Bearish Trend 4 days ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
74%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
57%
Bearish Trend 4 days ago
76%
Aroon
ODDS (%)
Bearish Trend 4 days ago
64%
Bullish Trend 4 days ago
74%
View a ticker or compare two or three
Ad is loading...
BVNRY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CRMD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CIRRX18.220.08
+0.44%
Cohen & Steers Real Estate Securities R
PGRSX9.760.01
+0.10%
Principal Global Real Estate Sec R6
MMNBX10.91N/A
N/A
MassMutual Diversified Value Y
KSMVX10.25-0.10
-0.97%
Keeley Small-Mid Cap Value A
NEEIX62.32-1.62
-2.53%
Needham Growth Institutional

BVNRY and

Correlation & Price change

A.I.dvisor tells us that BVNRY and GOVX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BVNRY and GOVX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BVNRY
1D Price
Change %
BVNRY100%
-14.24%
GOVX - BVNRY
28%
Poorly correlated
-6.90%
CRMD - BVNRY
24%
Poorly correlated
-6.09%
EXAI - BVNRY
23%
Poorly correlated
-11.68%
VRAX - BVNRY
23%
Poorly correlated
-5.79%
CMRX - BVNRY
22%
Poorly correlated
-4.32%
More